FDA-approved
Bones & muscles
Vosoritide
Evidence
FDA approved
Class
C-type natriuretic peptide analog
KEY TAKEAWAY
Vosoritide is a 39-amino-acid analog of C-type natriuretic peptide. It is sold as Voxzogo. The FDA approved vosoritide (Voxzogo) in 2021 to increase growth in children with achondroplasia whose growth plates are still open.
Written by the Veylo editorial team · Updated
November 2026
What it is
C-type natriuretic peptide analog
Approved for
Achondroplasia in children
Key fact
The FDA approved vosoritide (Voxzogo) in 2021 to increase growth in children with achondroplasia whose growth plates are still open.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Vosoritide is a 39-amino-acid analog of C-type natriuretic peptide. It is sold as Voxzogo.
It stimulates growth-plate cartilage to grow by activating the natriuretic peptide receptor B.
The FDA approved vosoritide (Voxzogo) in 2021 to increase growth in children with achondroplasia whose growth plates are still open.
Achondroplasia in children.
Injection-site reactions, low blood pressure and vomiting are the most common effects.
U.S. FDA prescribing information for Vosoritide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.